Agoracom Blog Home

Posts Tagged ‘Marijuana’

PRIMO Nutraceuticals $PRMO.ca – Consumers Clamor for #CBD as More Novel Uses are Purported $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 1:15 PM on Tuesday, February 11th, 2020

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

Consumers Clamor for CBD as More Novel Uses are Purported

  • CBD products overall are having a major impact on the global industry because they offer a number of therapeutic benefits without the psychoactive effects of THC
  • Currently, this segment of the cannabis industry is also gaining prevalence for its potential to treat serious medical conditions such as cancer, multiple sclerosis, Alzheimer’s, Parkinson’s, depression, and anxiety.

NEW YORK, Feb. 11, 2020 — Earlier in 2018, the Farm Bill restored industrial hemp to nationwide legal production for the first time since World War II. Removing hemp from the Controlled Substances Act of 1970 (CSA) also helped create a financial domino effect – eventually leading to mass-market retailers CVS Health, Rite Aid, and Walgreens Boots Alliance to carry hemp-CBD brands. Notably, cannabis-based oils have become widely popular because of their potent and immediate effects.

In fact, CBD products overall are having a major impact on the global industry because they offer a number of therapeutic benefits without the psychoactive effects of THC. Currently, this segment of the cannabis industry is also gaining prevalence for its potential to treat serious medical conditions such as cancer, multiple sclerosis, Alzheimer’s, Parkinson’s, depression, and anxiety. And as the U.S. hemp industry matures, it is expected to transition from being a seed, textile, and industrial product importer to a global exporter. And according to data compiled by Hemp Business Journal, a division of New Frontier Data, the total sales for the U.S. hemp industry totaled USD 820 Million in 2017. The research also suggests that the industry is expected to grow to USD 1.9 Billion by 2022 and at a CAGR of 14.4% during the 5-year period.

The 2018 Farm Bill, however, explicitly preserved the FDA’s authority to regulate products containing cannabis or cannabis-derived compounds under the FD&C Act and section 351 of the Public Health Service Act (PHS Act). This leaves a lot of uncertainties regarding which products can be sold legally. According to the FDA, it treats products containing cannabis or cannabis-derived compounds as it does any other FDA-regulated products – meaning they’re subject to the same authorities and requirements as FDA-regulated products containing any other substance.

This is true regardless of whether the cannabis or cannabis-derived compounds are classified as hemp under the 2018 Farm Bill. And despite the federal regulatory uncertainties, at least 70% of the 2019 U.S. hemp harvest is intended for extract production, with Colorado leading the nation in hemp cultivation and processing land area with over 80,000 acres reported.

“The 29 U.S. states reporting licensed hemp cultivation acreage total almost half a million acres in combined cultivation land area, which is a massive increase compared to 2018 figures of a total land area barely over 100,000 acres. While there continues to be uncertainty and a healthy amount of confusion around hemp cultivation for CBD production, it is clear that demand is nonetheless continuing to rise across the U.S.,” noted Giadha Aguirre de Carcer, New Frontier Data CEO and Founder. “As states issue more licenses, consumer demand increases, and mass-market retailers such as CVS and Walgreens continue to expand their own product offerings, we expect the FDA may be forced to provide further regulatory clarifications sooner rather than later.”

Source: https://www.prnewswire.com/news-releases/consumers-clamor-for-cbd-as-more-novel-uses-are-purported-301002483.html

Vertical Exploration $Vert.ca Moves Forward to Register its St-Onge Wollastonite as an Approved Supplement for the Canadian Agricultural and Cannabis Industries $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 8:28 AM on Tuesday, February 11th, 2020

VANCOUVER, BC / ACCESSWIRE / February 11, 2020 / VERTICAL EXPLORATION INC. (TSXV:VERT) (“Vertical” or “the Company”) is pleased to provide an update regarding registration of its high-quality St-Onge Wollastonite for use as an approved supplement for both the Canadian agricultural and cannabis/hemp industries.

Vertical and its distribution partner, Wollammo Distribution Inc. (Wollammo), have moved forward to seek registration of Vertical’s St-Onge Wollastonite as a Supplement under the Fertilizer Act established by the Canadian Food Inspection Agency (CFIA). Vertical and Wollammo have engaged Ms. Niki Nickel, Compliance Manager, QA, to help the companies move forward with the registration process in an expedited fashion, given the importance and market appeal that this registration will bring to Vertical and Wollammo.

Ms. Nickel has recently reviewed Wollammo’s compliance data documents and believes the Wollammo product, which consists of 100% St-Onge Wollastonite, meets the criteria for registration as a Supplement under the Canadian Fertilizer Act established by CFIA and the Safe Foods for Canada Act SOR 2018-108. Subsequently, a letter of intent will be filed as soon as possible for Vertical’s Wollastonite in the form of a Pre-Market Application Submission (PASO) at the Canadian Food Inspection Agency.

Wollammo’s compliance data shows that the St-Onge Wollastonite improves soil structure, supports plant growth and improves crop yields which are characteristics defined by CFIA as supplements under the Canadian Fertilizers Act and Regulations. Agriculture Canada Standards have been consolidated into the Safe Foods for Canada Act SOR 2018-108, which also includes related and consequential amendments to Section 88 of the Fertilizer Act and to Section 103 of the CFIA Act. Supplements registered under CFIA are therefore included in the Safe Foods for Canada Act, and can be used for Farm, Lawn and Garden uses.

Ms. Nickel, who has completed registrations in more than 60 Countries and U.S. States (including CFIA registration, REACH, and EPA in the U.S. States) and has also worked with several specialty fertilizer companies to complete label revisions and registration, states that “”I’m excited to help Wollammo move ahead with registration as a supplement with CFIA.”

Peter P. Swistak, President/CEO of Vertical Exploration Inc., commented: “I’m thrilled that, with the strong support of our distribution partner Wollammo, we have been able to move ahead so quickly to seek registration for Vertical’s Wollastonite under both the Agriculture Canada Standards Safe Foods for Canada Act SOR 2018-108 and the Canadian Fertilizer Act established by CFIA. Approval under these important Acts will pave the way for significant market awareness and future sales of our St-Onge Wollastonite, and also help provide verification that the Wollammo Wollastonite product has the highly sought after characteristics that agriculture and cannabis/hemp growers alike are looking for in a premium supplement.”

Vertical will provide a further update as soon as the registration process has been completed.

ABOUT VERTICAL EXPLORATION

Vertical Exploration’s mission is to identify, acquire, and advance high potential mining prospects located in North America for the benefit of its stakeholders. The Company’s flagship St-Onge Wollastonite property is located in the Lac-Saint-Jean area in the Province of Quebec.

ON BEHALF OF THE BOARD
Peter P. Swistak, President/CEO

FOR FURTHER INFORMATION PLEASE CONTACT:

Telephone: 1-604-683-3995
Toll Free: 1-888-945-4770

Empower Clinics $CBDT.ca Announces Strong Start to The Year with January 2020 Patient Visits Increasing by 188% $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:31 AM on Tuesday, February 11th, 2020
  • Announced that patient visits in corporate clinics increased by 188% in January 2020 versus the same period in 2019, with total patient visits of 1,750 in January 2020 compared to 607 in January 2019.

VANCOUVER, BC /February 11, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce that patient visits in corporate clinics increased by 188% in January 2020 versus the same period in 2019, with total patient visits of 1,750 in January 2020 compared to 607 in January 2019.

“January patient volumes were strong, setting the stage for potentially record first quarter patient visits, that are always focused on the patient experience, it’s a competitive advantage and I continue to be impressed with how our team members care for each and every patient they see.” said Steven McAuley, Chairman & CEO of Empower. “Looking forward, we are excited for our next franchise signings and the expansion of our product lines, adding to the in-clinic retail experience we are building.”

The Company utilizes it’s technology platform to communicate with patients by text message, email and call center ensuring appointments are confirmed and expected patient visits take place as planned.

The Company’s Sun Valley Health division also completed the set up and build out of it’s retail product counter and sales areas in it’s Tucson, AZ location, to showcase it’s CBD product line with over 50 unique SKU’s. Patients and customers can purchase product in clinic locations or online at www.sunvalleyhealth.com.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

CEO

[email protected]

604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

NORTHBUD $NBUD.ca – Everything Canadians need to know about Legalization 2.0 $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 3:51 PM on Monday, February 10th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Everything Canadians need to know about Legalization 2.0

  • Edibles, extracts, topicals, and vapes are finally legal in Canada. Billed as Legalization 2.0, the regulations came into effect on October 17, 2019 and products have slowly begun to trickle onto the market ever since.

By Leafly Canada Staff

Edibles, extracts, topicals, and vapes are finally legal in Canada. Billed as Legalization 2.0, the regulations came into effect on October 17, 2019 and products have slowly begun to trickle onto the market ever since.

From how to consume, to what to consume, here’s everything Canadians need to know about Legalization 2.0.

Edibles 101

Cannabis-infused edibles are now available for sale through licensed retailers in Canada, though there are strict rules around marketing and dosing, including a limit of 10 mg of THC per packaged item.  Edibles in the form of food products, lozenges, and beverages can produce effective, long-lasting, and safe experiences. These forms of cannabis can also produce unpredictable effects that may feel like overdose symptoms. The difference is, of course, the dose, although it’s worth noting that while consuming too much can feel very unpleasant, no one has ever died from it.

It can take anywhere from 30 minutes to four hours for an edible to fully kick in. Health Canada suggests that adults who use cannabis, regardless of how they consume it, shouldn’t combine it with alcohol, nicotine or other drugs.

Source: https://www.leafly.com/news/strains-products/legalization-2-0-guide-canada

PRIMO Nutraceuticals Inc. $PRMO.ca – #CBD’s Touted Therapeutic Benefits Help Loosen Regulatory Constraints $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 12:10 PM on Monday, February 10th, 2020

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

CBD’s Touted Therapeutic Benefits Help Loosen Regulatory Constraints

  • Global cannabidiol market is expected to reach USD 9.69 Billion by 2025 while registering a CAGR of 32.6% during the forecast period.

NEW YORK, Feb. 10, 2020 – Most regions that have approved medical cannabis typically see doctors prescribe CBD-based medications to their patients. CBD, or cannabidiol, is a derivative of the hemp plant, yet is unlike its counterpart, THC, which is derived from the marijuana plant. Nowadays, the FDA acknowledges that CBD can possibly become a legitimate alternative medical treatment to a number of traditional therapeutics, further highlight the health benefits associated with the compound. However, the agency is requiring researchers to provide more data on the efficacy of CBD in order for CBD to become an approved medicinal treatment, prompting them to conduct large-scale clinical trials. “As legislation expands rapidly worldwide, the volume of efficacy data is growing, as are legitimate clinical trial studies,” says Liam McGreevy, Chief Executive Officer of Ethnopharm, a European cannabis company specializing in genetics and distribution, “This data will enable us to better understand the effects of the various cannabinoids and terpenes, their synergistic effect and how their impact links to the individual’s genetics or biomarkers.

This data is key to understanding the most effective combinations and strengths for various conditions, moving towards targeted personalized medicines.” And according to data compiled by Grand View Research, the global cannabidiol market is expected to reach USD 9.69 Billion by 2025 while registering a CAGR of 32.6% during the forecast period. Global Payout, Inc. (OTC: GOHE), Auxly Cannabis Group Inc. (OTC: CBWTF), Puration Inc. (OTC: PURA), Green Organic Dutchman Holdings Ltd. (OTC: TGODF), Liberty Health Sciences Inc (OTC: LHSIF)

As the cannabis industry continues to develop, lawmakers and federal agencies are actively working towards expanding the market. Recently, the U.S. Department of Agriculture (USDA) provided an update on its interim final rule process for hemp. According to the USDA, hemp production in the U.S. has seen a resurgence in the last five years; however, it remains unclear whether consumer demand will meet the supply. High prices for hemp, driven primarily by demand for use in producing CBD, relative to other crops, have also driven increases in planting. As such, producer interest in hemp production is largely driven by the potential for high returns from sales of hemp flowers to be processed into CBD oil.

And after extensive consultation with the Attorney General, the USDA issued the following interim final rule to establish the domestic hemp production program and to facilitate the production of hemp, as set forth in the 2018 Farm Bill: The USDA upholds the 0.3% threshold as out of its jurisdictional hands as written into the law. Furthermore, the lack of remedies for testing noncompliance raised suggestions that farmers be allowed to ship to processors who could remove the THC to keep the crop viable. Another subject of worry was the requirement (as described in the Federal Register) that laboratories be certified by the Drug Enforcement Administration (DEA), and crops tested within 15 days prior to harvest. Yet, by the end of January, only 44 labs existed to support more than 16,000 licensed farmers. Accordingly, the industry expects to remain bureaucratically constrained yet again after other fundamental supply-chain bottlenecks limited output and producers’ ability to bring their crops to market.

Source: https://www.prnewswire.com/news-releases/cbds-touted-therapeutic-benefits-help-loosen-regulatory-constraints-301001669.html

CLIENT FEATURE: Vertical Exploration $VERT.ca Partners with AREV Brands to Distribute Wollastonite to the Cannabis and Hemp Industries $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 4:06 PM on Tuesday, February 4th, 2020

Vertical Exploration is developing its St. Onge Wollastonite as a soil additive for optimizing marijuana growth. Recently engaged AGRINOVA’s Phase 1 Reseach program also demonstrated Wollastonite can potentially become BNQ certified for agricultural use in Quebec. Recently signed distribution agreement with AREV Brands International to Supply St-Onge Wollastonite to the Cannabis and Hemp Industries. Click Here for More Info.

  • Definitive distribution agreement to partner on the sale of Vertical’s wollastonite from its world-class St-Onge Deposit in place.
  • Supplying the fast growing cannabis and hemp industries.
  • Vertical’s high quality Wollastonite has been shown to be beneficial to cannabis plants in a variety of ways
  • In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium.
  • The high-grade St-Onge Wollastonite deposit has pit-constrained mineral resources of: 7,155,000 tonnes Measured@ 36.20% Wollastonite & 6,926,000 tonnes Indicated@ 37.04%
  • B.C. Buds Testing Confirmed Wollastonite is critical to marijuana growers
  • Engaged AGRINOVA over the past year to conduct research and testing of Vertical’s St-Onge wollastonite on a range of important agricultural end uses.

WOLLASTONITE

  • St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.
  • Wollastonite is a calcium inosilicate mineral that may contain small amounts of ironmagnesium, and manganese substituting for calcium
  • Research and testing in the Phase 1 program for use in cannabis growth was managed and monitored by AGRINOVA, a highly-regarded Center for Research and Innovation in Agriculture in Quebec

St-Onge-Wollastonite Deposit:

HUB on Agoracom

FULL DISCLOSURE: Vertical Exploration is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: NORTHBUD $NBUD.ca Multinational #cannabis company laying the foundation to aggressively pursue the greatest recreational markets $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 2:32 PM on Tuesday, February 4th, 2020

Salinas greenhouse facility is currently operating 60,000 sq. ft. licensed canopy and contains ample room for expansion. The facility is also licensed for manufacturing and for distribution.

  • In late December completed first harvest at Salinas, California cultivation facility.
  • Harvested 2,687 plants that were included in the acquisition of the Qlora Group.
  • Anticipates completing testing and sale of the product in late January 2020, which will represent the first revenue generated by the Company in California.
  • Also completed an in-depth review and analysis of both the infrastructure and cultivation practices and will be implementing significant efficiencies over the course of the next four harvests.
  • Anticipates continual harvests of 2,000-3,000 plants every 25 days, with quality and yield improving with each harvest.
  • Product will be sold via wholesale agreements to existing Qlora clients in the interim as company prepares for the launch of NORTHBUD branded flower products in California in the third quarter of 2020. 

Cannabis Production Facility in Reno, Nevada

Assumed control of Nevada operation licensed for cultivation, manufacturing and distribution throughout the state.

  • Announced the completion of the first harvest of approximately 175 indoor grown plants
  • Upon the completion of testing and processing, the product will be distributed as NORTHBUD flower, pre-rolls and infused pre-rolls into selected Nevada dispensaries.
  • The launching of NORTHBUD branded products into Nevada marks a significant milestone for the Company.

Request for Outdoor Cultivation License:

  • In the context of a regular follow-up communication with Health Canada, representatives of the Company received verbal feedback that the application review is complete and the reviewers do not have any more questions
  • Subject to the re-submission of a required foreign police certificate related to one of the foreign directors of the Company, the Company will be in the final queue for receiving its licence.
  • The Company is confident that it will be able to file the certificate promptly; however, there can be no assurance as to the exact timing of the issuance of the licence by Health Canada or whether the Company will receive any final request from Health Canada.

FULL DISCLOSURE: NORTHBUD is an advertising client of AGORA Internet Relations Corp.

Spyder $SPDR.ca Announces Canceling of the Non-Brokered Financing, Secures $442,000 Bridge Loan from Management and Insiders and Appoints New Board Member $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:52 AM on Monday, February 3rd, 2020
  • Cancelled the previously announced (January 13, 2020) non-brokered private placement of senior secured convertible debentures in the aggregate principal amount of up to $1,500,000.

Vaughan, Ontario–(February 3, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) would like to announce that it has cancelled the previously announced (January 13, 2020) non-brokered private placement of senior secured convertible debentures in the aggregate principal amount of up to $1,500,000.

BRIDGE LOAN SECURED

To ensure its short-term working capital needs are covered, Spyder has secured bridge loans in the amount of $442,000 provided primarily by management and insiders in the Company. The bridge loan will have the following attributes. The term matures on July 25, 2020, bears interest at 12% per annum payable monthly in arrears and Spyder may repay all or a portion there-on at any time during the period. To secure the bridge loans, Spyder granted a security interest over all of the personal property, assets and undertakings of Spyder.

“Securing a bridge loan for nearly half a million dollars largely from management and insiders shows confidence in Spyder’s ability to execute on its business model. We are excited to begin this next phase in Spyder’s development,” says Dan Pelchovitz, CEO of Spyder.

APPOINTMENT OF NEW BOARD MEMBER

In addition, Spyder is pleased to announce that Mr. Ben Leung has been appointed as a director. Ben is an accountant with over 28 years of financial accounting and management experience in both private industry and public practice. He is currently the Chief Financial Officer of Cultivate Capital Corp., a company investing and operating in the cannabis and hemp industry throughout North America. Over the past 2 years, Ben has acquired strong working knowledge of this industry and was responsible for leading strategic discussions, acquisitions, budgeting, financing, financial reporting and internal controls. Most recently, Ben was the controller, and then promoted to CFO of QE2 Acquisition Corp. He served a critical role in getting the corporation listed on the TSXV. His experience includes financial reporting, taxation, risk management, human resources and corporate governance. Prior to that, he was a senior manager with a Calgary based accounting firm and focused on the audit and assurance department. He has held controllership positions with publicly listed companies in the pharmaceutical, oil and gas, and manufacturing industries.

The Company would also like to announce the resignation of Mike Lerner from its Board of directors. The Company would like to thank Mr. Lerner for his time and commitment during his tenure on the Board.

MI 61-101 DISCLOSURE

Several directors and insiders as defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101“), participated in the bridge loans, either directly or indirectly, therefore the bridge loans constitute a “related party transaction” within the meaning of MI 61-101. In its consideration and approval of the bridge loans, the board of directors of the Company determined that the bridge loans are exempt from the formal valuation and minority approval requirements of MI 61-101 on the basis that the fair market value of loans to related parties does not exceed 25% of the market capitalization of the Company, in accordance with Sections 5.5 and 5.7 of MI 61-101.

The Company did not file a material change report more than 21 days before the closing of the bridge loans as the details of the bridge loans, and the confirmation of insider participation in the bridge loans, was not definitively known to the Company until the date of the closing of the bridge loans and the board of directors determined that it was in the best interests of the Company to close the transaction as soon as practicable.

About Spyder Cannabis Inc.

Spyder is a CBD and Cannabis retailer that operates in jurisdiction where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of CBD in the United States, the second is the sale of smoking cessation and cannabis products in Ontario; and the third is the sale of cannabis products in Alberta.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward- looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer Telephone: 1.888.504.7737
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52035

Imerys Closure of Wollastonite Mine a Supply and Demand Opportunity for Vertical Exploration’s St. Onge Deposit SPONSOR: Vertical Exploration $VERT.ca $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 2:17 PM on Thursday, January 30th, 2020
http://blog.agoracom.com/wp-content/uploads/2019/11/VERT-square-logo.png

SPONSOR: Vertical Exploration is developing its St. Onge Wollastonite as a soil additive for optimizing marijuana growth. Recently engaged AGRINOVA’s Phase 1 Reseach program also demonstrated Wollastonite can potentially become BNQ certified for agricultural use in Quebec. Recently signed distribution agreement with AREV Brands International to Supply St-Onge Wollastonite to the Cannabis and Hemp Industries. Click Here for More Info.

The former NYCO Minerals wollastonite mine. Photo by Carl Heilman II.

The Imerys ore processing operation in Willsboro is closed until further notice for cleaning of asbestos that has contaminated its wollastonite products.

A representative of union workers at the plant said the plant shutdown is temporary, and a plant spokesman preferred to call it a suspension of work.

The France-based Imerys, which acquired the former NYCO Minerals mining and processing operations in 2016, learned of the problem this summer from a customer. The closure brings the latest round of job uncertainties for a mine that New York voters in 2013 agreed to support by amending the state constitution to allow an Adirondack land swap that has yet to happen.

“A third party told them about asbestos. It’s in the ore,” said Ray Bettis, a representative of the United Auto Workers, the union for about 40 workers at the processing operation in Willsboro.

He said the entire workforce was called into a meeting on Wednesday afternoon. Many were relieved that the announcement was not that the plant was closing altogether, Bettis said.

Ryan Toohey, a spokesman for the company, confirmed the contamination problem and said the company intends to reopen for business. He emphasized the plant’s difficulties are not related to the bankruptcy protection sought on Wednesday by Imerys Talc America.

The Chapter 11 bankruptcy announcement was related to lawsuits alleging that the Imerys Talc subsidiaries are liable for products that have caused ovarian cancer and asbestos-related mesothelioma.

Wollastonite is a mineral used in ceramics, paints, plastics and auto-body parts.

In Essex County, the plant closure also worried workers because of repeated statements by company officials that sales of wollastonite at Willsboro, mined by Imerys in nearby Lewis, have been weak.

The plant has been closed since its third shift on Tuesday. The workers are being paid during the closure, Bettis said, and many will return on Monday to clean the premises. They will wear masks, he said.

Tests revealed trace levels of asbestos, and only in some products, the company said, and no contamination in the plant’s air. Toohey issued a statement that said Imerys has no reason to believe the wollastonite or the products sold  are unsafe for handling and use.

“Out of an abundance of caution, we are temporarily suspending production and are working to identify the earliest possible date to resume production with ore that meets our standards,” the company said. “We remain committed to producing high-quality wollastonite in Willsboro.”

The company, which has cut staff and farmed out some work in the past few years, has 59 employees. It had employed more than 100 six years ago.

It will be throwing out tons of ore and product from the past 12 months. When workers clean the plants in Willsboro they will be wearing enhanced safety gear because of expected dusty conditions.

Mark Buckley, a former administrator at the plant who served as its safety and health director, said an asbestos contamination issue arose about 16 years ago when a customer discovered the problem. At that time, the company closed for a few days of cleaning and investigation. Workers needed to be fitted for masks for protection then. The root of the asbestos was a rock formation adjoining the ore mine, he said.

The new issue surfaced amid inspections by the U.S. Mine Safety and Health Administration, which sends inspectors into the plant at least twice a year. Already, the plant has received 33 citations for violations this year, according the MSHA web site. An MSHA spokesman was unavailable.

The plant  has a long history as a major employer for mining and plant processing jobs in the Adirondack hamlets of Lewis and Willsboro, though Imerys has discontinued its mining employment and contracts the work to a Vermont excavator.

The plant also received the uncommon opportunity from New York voters to swap state forest preserve land for the rights to mine wollastonite in an area of Lewis known as Lot 8. Imerys has yet to take advantage of that opportunity, granted after heavy lobbying from the former owners who said they needed Lot 8 to preserve jobs. Voters approved a trade of 200 acres in the Jay Mountain Wilderness for lands of equal or greater value.

John Brodt, a spokesman for the Imerys mining division, said Imerys intends to continue testing the ore at Lot 8. Imerys wants to capitalize on the mining opportunity extended by voters in 2013, he said.

An application, submitted late last year, is pending before the state Department of Environmental Conservation to conduct horizontal drilling from the company’s land adjacent to Lot 8, he said. The goal is to add to previously collected test data before determining the value of Lot 8.

If the company and the state arrive at a land swap deal, the Lot 8 acquisition could happen in 2022, Brodt said.

SOURCE: https://www.adirondackexplorer.org/stories/asbestos-contamination-closes-adirondack-mine

Empower Clinics $CBDT.ca – Next Decade in #Cannabis Education: Where Do We Go From Here? $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:27 PM on Thursday, January 30th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

Next Decade in Cannabis Education: Where Do We Go From Here?

Cannabis education has seen remarkable momentum over the past 10 years.

In 2010, only a handful of U.S. states had medical cannabis programs. No adult-use legislation was passed anywhere in the country (or the world). Mainstream images of cannabis were mostly outdated stoner stereotypes in movies and television.

Much of America still viewed cannabis from a place of fear—a plant to be demonized, avoided and eradicated.

In 2011, the tide turned for cannabis. Support for cannabis legalization in the U.S. reached 50% for the first time in recorded history. This upward trend continues to this day; Americans are increasingly becoming more open-minded about cannabis being good for society.

Today, medical cannabis is legal in 33 states and 11 states have legalized for adult use (plus Washington D.C. has legal medical and adult use). What an incredible shift in just 10 short years!

Other countries—Canada, Georgia, South Africa and Uruguay—have outright lifted cannabis prohibition. Chile, Colombia, Poland, Thailand, Italy, Greece, Germany, Norway and many others now have medical cannabis laws. The U.S. is waking up to the power and benefits of cannabis, and it’s becoming a global revolution.

How Cannabis Education Got Us Here

The focus in cannabis education over the past 10 years has been split between two-prongs—consumer-facing and legislative-facing.

Steve DeAngelo, the family of Charlotte Figi and many other advocates in the space have exponentially educated the public about the medical and wellness benefits of cannabis. Cannabis advocates demonstrate that the plant is safe, with distinctive life-enhancing and life-saving properties.

The mission behind these advocates is to share stories and provide credible information on the plant’s safety profile, as well as health, happiness and wellness benefits. This led to the U.S. going from barely 50% approval for legalization in 2011 to a 66% approval rating in 2018.

Legislation-facing cannabis education has primarily been about changing medical cannabis laws. This way, Americans can access tested medical cannabis that is safe, and businesses can operate legally.

It’s only been in the last few years that adult use has started to gain steam. This side of cannabis education involves helping the government understand medical benefits, economic benefits, social benefits, tax benefits and job-boosting properties of cannabis.

How do we help spread this understanding? By sharing the latest data. The cannabis industry is generating U.S. employment—including ancillary sectors—supporting more than 500,000 jobs in 2019. And when it comes to taxes, the Institute on Taxation and Economic Policy estimated state and local cannabis tax revenue in the US to be $1.6 billion for 2019.

Other benefits of legal cannabis catching the eye of legislators include revitalization, improved security and lighting of once-abandoned areas now home to cannabis companies. Townships and counties are also reporting a reduction in violent crime and an increase of residential property values in areas where cannabis dispensaries are located.

New regulations also free law enforcement and judicial resources to focus on serious crimes, rather than going after cannabis businesses, patients and consumers.

However, as this new, rapidly emerging industry begins to find its feet, the biggest challenges and growing pains in cannabis are becoming more evident with every passing week.

This is where the next phase of cannabis education comes into play.

Cannabis Education in 2020 and Beyond

In this new decade, cannabis education is taking on an evolved focus. With cannabis touching many different sectors of society because of legalization, it’s now time to educate the specialists.

Ten years from now, we’ll be talking about how doctors have integrated cannabis into healing protocols, how pharmacists are properly prescribing cannabis and how health insurance is covering cannabis medicine under policies.

We’ll be talking about how retail establishments around the world are carrying cannabis and CBD products to build businesses and bring safe, legal access to consumers and patients across the globe.

We will see law enforcement adopting an entirely new framework for enforcing cannabis policy, one that respects people’s rights and doesn’t treat innocent bystanders as criminals.

This is where cannabis is heading, and to get there, we need specialized education that brings specialized knowledge to all individual groups from health care professionals to law enforcement officials and beyond.

Training a New Workforce

There are brand new, fast-growing cannabis industries to support.

The range and number of careers in cannabis today is greater than most Americans realize. Earlier you read that there’s 500,000+ jobs in and around cannabis—that’s a 76% increase from cannabis jobs in 2018.

This is a fast-growing job market in which people need to be trained in ALL areas of cannabis that require specialized knowledge to operate, including:

  • Business
  • Banking & Finance
  • Agriculture & Cultivation
  • Distribution
  • Legal & Compliance
  • Medical
  • Manufacturing & Product Development
  • Marketing & PR
  • Retail
  • Sales
  • Science & Extraction
  • Tech
  • Much more.

Colleges, universities and schools will need to get more involved in cannabis to help train and educate an entirely new workforce. Collaborating with higher ed will be a huge sector of development for cannabis education in this decade.

Ten years from now, we’ll no doubt see with a sense of surprise how much progress has been made in cannabis. The industry will become a boring, everyday topic, fully legitimized and integrated across the globe. Cannabis will improve quality of life for countless Americans, fueling the careers of millions—and we’ll be wondering: what took us so long?

Max Simon is the founder and CEO of Green Flower, the global leader in cannabis education and training.

Source: https://observer.com/2020/01/cannabis-education-next-decade/